Value in new medicines and longer strides

https://unauthorised investment advice/experts/value-in-new-medicines-and-longer-strides/

So the CEO is now sharing his extensive biotech industry and stock picking experience in this puff piece?? The comment:
"If you look at some of the recent ‘winners’ in Australian biotechnology, real value creation has taken three years or more. One example is the eye disease house Opthea (ASX:OPT)."
is of concern as (and no particular criticism of OPT) this stock has seen a spectacular evaporation of value with the slip from $3.15 to $1.95 in the past few months on the back of a US listing. Let alone how much has been lost since foundation as Vegenics.

The comment:
"Are the board and key management striving to add value, or more interested in the lifestyle benefits attached to running a listed company?"
is just simply gratuitous. He should be careful about making statements like that until real sustainable value has been created in EX1....and that is a long way off IMHO. The fees earned by NEDs do not support any kind of "lifestyle benefit" and when coupled with liabilities who the heck would want to be involved for the fees alone.